Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Rosenblatt Maintains Neutral on ViacomCBS, Lowers Price Target to $42

Rosenblatt analyst Mark Zgutowicz maintains ViacomCBS (NASDAQ:VIAC) with a Neutral and lowers the price target from $45 to $42.

byBenzinga Newsdesk

November 10, 2021

1 minute read

Rosenblatt analyst Mark Zgutowicz maintains ViacomCBS (NASDAQ:VIAC) with a Neutral and lowers the price target from $45 to $42.

News

‘Maine Senate Defeats Drug Decriminalization Bill That Cleared The House’ -MarijuanaMoment

By Michael Horton

July 1, 1:30 PM

https://www.marijuanamoment.net/maine-senate-defeats-drug-decriminalization-bill-that-cleared-the-house/

ACB

Do Gig Workers Want To Be Employees? It Depends Who You Ask

By FreightWaves

June 4, 11:12 AM

In the last few weeks, there have been surveys that suggest that rideshare drivers and other independent contractors would rather have full-time employment – except for those who don't.

DASH

Global
News

South African President Cyril Ramaphosa Says J&J Expects To Send 2M Doses Of COVID-19 Vaccine To South Africa By End Of Jun.

By Benzinga Newsdesk

June 15, 2:26 PM

-Reuters

JNJ

BeiGene Reports Will Present Clinical Results, Biomarker Data On Tislelizumab In Solid Tumors At American Association For Cancer Research Meeting

By Benzinga Newsdesk

April 8, 7:03 AM

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient characteristics driving

BGNE

Rosenblatt Maintains Neutral on ViacomCBS, Lowers Price Target to $42

Related Posts

‘Maine Senate Defeats Drug Decriminalization Bill That Cleared The House’ -MarijuanaMoment

Do Gig Workers Want To Be Employees? It Depends Who You Ask

South African President Cyril Ramaphosa Says J&J Expects To Send 2M Doses Of COVID-19 Vaccine To South Africa By End Of Jun.

BeiGene Reports Will Present Clinical Results, Biomarker Data On Tislelizumab In Solid Tumors At American Association For Cancer Research Meeting